Arca
Skip to content
Tools
Tools

Anterior uveitis

Drug research and approvals for anterior uveitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 30 studies of anterior uveitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 3 approved and 4 open orphan designations naming it.

  • Recruiting worldwide: 30
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 3
  • EU medicines: 0

Recruiting now

Newest posted first, of 30 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 6

Phase 2 4

Phase 1 or earlier 2

How its trials ended

50 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 12 whose ending is known, 83% met their primary endpoint, 0% missed it and 17% stopped early.

  • Completed, result not reported2346%
  • Met its primary endpoint1020%
  • Status unknown918%
  • Ongoing612%
  • Stopped: other or unclear24%

FDA orphan designations

Approved first, then open designations, newest first
Sep 28, 2018HumiraTreatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and olderAbbVie, Inc.Approved
Jun 30, 2016HumiraIndicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patientsAbbVie, Inc.Approved
Jun 13, 2012DurezolTreatment of endogenous anterior uveitisAlcon Pharmaceuticals. Ltd.Approved
Oct 4, 2023MethotrexateTreatment of non-infectious intermediate, posterior, or pan uveitis or chronic non-infectious anterior uveitisNordic Group B.V.Designated
Jun 22, 2022AAV2.adalimumabTreatment of non-infectious intermediate, posterior, or panuveitis or chronic non-infectious anterior uveitisKriya Therapeutics, Inc.Designated
Dec 7, 2021TacrolimusTreatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitisBioNanoSim Ltd.Designated
Jun 3, 2019Ac-Nle-cyclo-(Glu-His-D-Phe-Arg-Dap)-Trp-NH2Treatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitisPalatin Technologies, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.